Breaking AI & Tech News Analyzed

Retatrutide Delivers Up to 28% Body‑Weight Reduction in Phase 3 StudyA new weight‑loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight, Eli Lilly announced on Thursday. Phase 3 Trial Design and Dosing RegimenThe Indiana‑based company randomized 2,339 adults with obesity or overweight and at least one weight‑related comorbidity (no diabetes) to receive Retatrutide at 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. The drug is a once‑weekly triple hormone receptor agonist targeting GLP‑1, GIP, and glucagon. Quantitative Outcomes and Safety ProfileAverage weight loss: 70.3 lb (28.3%) at the 12 mg dose.Average loss at 9 mg: 64.4 lb (25.9%).Average loss at 4 mg: 47.2 lb (19.0%).45.3% of 12 mg participants lost ≥30% of body weight.65.3% reduced BMI below 30; 37.5% of those starting with BMI ≥ 40 achieved this.Side‑effects increased with dose: nausea (28.6%‑42.4%), diarrhea (25.2%‑34.1%), vomiting (up to 25%).For comparison, Zepbound yields 15‑20% loss over 72 weeks and Wegovy 14‑19% over 64‑72 weeks. Implications for the Obesity‑Drug LandscapeThe magnitude of loss positions Retatrutide as the most effective pharmacologic option to date, potentially shifting prescriber preference away from existing GLP‑1 monotherapies. Its triple‑agonist mechanism adds glucagon, a hormone absent from current products, which may enhance metabolic control and appetite suppression. Future Outlook: Approval Path and Market PotentialAnalysts expect regulatory submissions within the next year, with a likely U.S. FDA review in 2027. If approved, Retatrutide could capture a sizable share of the rapidly expanding obesity‑treatment market, prompting competitors to explore multi‑agonist formulations.

A new large‑scale randomized trial presented at the European Congress on Obesity in Istanbul indicates that the oral GLP‑1 antagonist orforglipron can help patients retain the majority of weight lost with injectable therapies such as tirzepatide (Mounjaro) and semaglutide (Wegovy).Trial Shows Oral Orforglipron Preserves Most Weight After Switching from InjectablesThe study, funded by Eli Lilly, followed 376 US patients who had been on tirzepatide or semaglutide injections for 72 weeks and then randomized them to a daily orforglipron tablet or placebo for an additional year.Participants were previously on weekly GLP‑1 jabs that typically produce 15‑20% body‑weight loss.After the injection phase, subjects were switched to oral therapy or placebo for 12 months.Primary endpoint: proportion of weight loss retained at 12 months.Quantitative Outcomes: 75% vs 49% Retention for Tirzepatide Users, 80% vs 38% for Semaglutide UsersWeight‑loss maintenance differed markedly between the pill and placebo groups:Tirzepatide cohort: 75% of lost weight retained with orforglipron vs 49% with placebo.Semaglutide cohort: 80% retained with the pill vs 38% with placebo.Secondary benefits—blood pressure, cholesterol, and glycaemic control—were also sustained in the pill arm.Implications for Obesity Management and Healthcare CostsExperts highlighted the broader significance:Dr Louis Aronne (Weill Cornell Medicine) emphasized that treating obesity directly can simultaneously improve glucose, lipid, and blood‑pressure metrics.Dr Marie Spreckley (University of Cambridge) noted patient preference for oral therapy due to convenience, storage, and lower cost.Dr Simon Cork (Anglia Ruskin University) warned that injectable GLP‑1 drugs, while highly effective, are expensive and limit long‑term accessibility for both private payers and the NHS.The findings suggest a potential shift toward oral agents that maintain efficacy while reducing financial and logistical burdens.Future Outlook: Oral GLP‑1 Therapies Could Redefine Chronic Obesity CareIf further trials confirm these results, orforglipron could become a cornerstone of chronic obesity management, enabling earlier intervention (BMI 25‑27) and possibly preventing progression to severe obesity.Regulators and payers will likely scrutinize cost‑effectiveness models, but the prospect of a cheap, daily tablet that sustains weight loss may reshape treatment algorithms worldwide.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Donald Trump has repeatedly framed inflation as a "hoax" and declared that he has "won affordability," yet independent analyses reveal that his touted initiatives deliver only marginal relief for most Americans.One of his most publicized programs, the TrumpRX prescription‑drug platform, lists just 61 medications out of the thousands needed nationwide. Moreover, price comparisons show that a medium dose of Wegovy costs $349 on TrumpRX, while the same dose sells for $163 in Japan and $198 in Germany. Similar gaps appear for diabetes drug Xigduo and autoimmune medication Xeljanz, which are significantly cheaper abroad.The website markets itself as a solution for uninsured, cash‑paying patients, but it does nothing for the roughly 85 % of Americans who already have prescription coverage.On housing, Trump’s executive order banning Wall Street firms from buying single‑family homes is unlikely to move the needle. Institutional investors own only about 2 % of such homes, while the nation faces a shortage of roughly 4.7 million units, according to Zillow. The ongoing war in Iran has also pushed mortgage rates higher, further straining affordability.Gasoline prices have surged since the Iran conflict began, climbing to an average of $4.10 per gallon – a 37 % increase from the pre‑war level of $2.98.Food costs tell a similar story. The Consumer Price Index shows a 3.1 % rise in overall food prices from February 2025 to February 2026, with coffee up 18.4 %, beef up 14.4 %, and fresh vegetables up 5.4 %. Tariffs championed by the administration have contributed to these hikes.International bodies echo domestic concerns. The OECD projects U.S. inflation to exceed 4 % this year, largely driven by the Iran war, a level higher than the 3 % rate recorded at the end of the Biden administration.Trump also claims to have eliminated taxes on overtime and Social Security benefits. In reality, overtime earnings are still subject to federal income tax on the base wage and to full Social Security and Medicare payroll taxes. Only the overtime premium enjoys a partial tax break. Likewise, more than half of Social Security recipients will continue to owe income tax on their benefits, contradicting the administration’s “no‑tax” narrative.Other initiatives, such as the “Trump Accounts” child‑savings program, provide a one‑time $1,000 seed deposit and allow families to contribute up to $5,000 annually. While beneficial for affluent households, the scheme offers limited assistance to families living paycheck‑to‑paycheck.Policy decisions have also raised costs for vulnerable groups. By opposing extensions of Obamacare subsidies, average health‑care premiums have risen by over 20 % for more than 20 million people. Simultaneously, proposed cuts to LIHEAP threaten heating and cooling assistance for roughly 6 million low‑income households.In sum, Trump’s affordability rhetoric serves more as political branding than substantive economic relief. The modest scope of his programs and the persistence of rising prices suggest that most working‑class Americans will see little improvement in their day‑to‑day expenses.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.

Scientists have made a groundbreaking discovery that could lead to the development of new obesity drugs. By studying the unique metabolic abilities of pythons, researchers have identified a molecule that appears to play a crucial role in regulating appetite and weight loss. The molecule, called pTOS, was found to increase significantly in the blood of pythons after they eat, and when administered to obese mice, it led to a significant reduction in food intake and a 9% loss of body weight over 28 days. The discovery could lead to the development of new obesity drugs that work in a different way to existing medications, such as GLP-1 medications like Wegovy. Unlike these medications, which can have side effects such as nausea and stomach pain, pTOS appears to act on the brain's appetite centers, reducing food intake without these adverse effects. The researchers, led by Dr. Jonathan Long from Stanford University and Prof. Leslie Leinwand from the University of Colorado Boulder, published their findings in the journal Nature Metabolism. They believe that pTOS, which is naturally produced by the snake's gut bacteria and also found in human urine, could be a safe and effective treatment for obesity. While further research is needed before the findings can be applied clinically, the discovery is seen as a promising step towards the development of new obesity treatments. The study's results suggest that pTOS could be a potential therapeutic target for the treatment of obesity and related metabolic disorders.